Prevalence of risk factors in men with premature coronary artery disease

https://doi.org/10.1016/0002-9149(91)90924-AGet rights and content

Abstract

The prevalence of modifiable cardiovascular risk factors (systemic hypertension, diabetes mellitus, cigarette smoking, low-density lipoprotein [LDL] cholesterol ≥ 160 mg/dl and high-density lipoprotein [HDL] cholesterol <35 mg/dl) was determined in 321 men <60 years of age (mean ± standard deviation 50± 7) with premature coronary artery disease (CAD) documented at coronary angiography. The prevalence of these risk factors was markedly different than in the Framingham Offspring Study population, used here as a comparison group. In the patients with CAD, only 3% had no risk factor (other than male sex), compared with 31% in the Framingham Offspring Study subjects. Most patients with CAD (97%) had ≥ 1 additional risk factor. When the patients with CAD were divided by age groups (40 to 49 years [n = 109], 50 to 59 [n = 191]), no significant differences were observed in the prevalence of risk factors between the young and older patients. The prevalence of systemic hypertension (41 vs 19%, p <0.001), diabetes mellitus (12 vs 1.1%, p <0.001), cigarette smoking (67 vs 28%, p <0.001) and HDL cholesterol <35 mg/dl (63 vs 19%, p <0.001) was markedly higher in the patients with CAD than in Framingham Offspring Study subjects, whereas the prevalence of LDL cholesterol ≥ 160 mg/dl was not significantly different between patients with CAD and Framingham Offspring Study sub jects (26 vs 26%). The use of β-adrenergic blockers was associated with a decreased prevalence of elevated LDL cholesterol and an increased prevalence of low HDL cholesterol, compared with patients not receiving this class of medication. When applying the guidelines of the National Cholesterol Education Program to patients with established CAD, only 52% had total cholesterol levels ⩾200 mg/dl and thus nearly half (48%) would not undergo further screening for lipoprotein abnormalities. In the group of patients with a total cholesterol <200 mg/dl, 75% had a low HDL cholesterol (<35 mg/dl). It is recommended that in men with established CAD, and in those with ≥ 1 additional risk factor, fasting triglyceride and HDL cholesterol levels be determined in addition to total cholesterol.

References (30)

  • Clofibrate and niacin in coronary heart disease

    JAMA

    (1975)
  • The Lipid Research Clinics Coronary Primary Prevention Trial Results. I. Reduction in incidence of coronary heart disease

    JAMA

    (1984)
  • The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering

    JAMA

    (1984)
  • M.H. Frick et al.

    Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia

    N Engl J Med

    (1987)
  • Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults

    Arch Intern Med

    (1988)
  • Cited by (237)

    • A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

      2015, Atherosclerosis Supplements
      Citation Excerpt :

      Although low HDL-c is predictive of increased CV risk, the complexity of its metabolic interrelationship with additional risk factors (e.g. LDL-c and triglyceride levels) must be considered. The prevalence of low HDL-c and high triglyceride levels in patients with proven CV disease has been evaluated in a number of studies and shows the importance of AD as a potential CV risk factor [20,21]. Furthermore, data from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myo cardial Infarction), ACCORD-Lipid (Action to Control Cardio vascular Risk in Diabetes), IDEAL (Incremental Decrease in End Points through Aggressive Lipid Lower ing) and TNT (Treating to New Targets) studies demonstrate that higher triglyceride levels are associated with higher rates of death and major CV events [22,23].

    View all citing articles on Scopus

    This study was supported by Grant HL 35243 from the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, and by Contract 53-3K06-5-10 from the U.S. Department of Agriculture Research Service, Washington, D.C. Dr. Genest was supported by a Fellowship of the Medical Research Council of Canada, Ottawa, Ontario, Canada.

    View full text